PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2025Nature Medicine130 citationsOpen Access

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SUSaad Z. UsmaniTFThierry FaçonVHVânia Hungria

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Usmani et al. (2025) studied this question.

synapsesocial.com/papers/6a7e83c4d14c4cd804797d8bhttps://doi.org/10.1038/s41591-024-03485-7
View Full Paper
Ask AI
Bookmark
Share